Seaside Therapeutics LLC
Industry
- Pharmaceuticals
- Biotechnology
- Drug Discovery Technologies
Latest on Seaside Therapeutics LLC
It was old home week at Keeping Track, featuring the return of two previously withdrawn new drug applications and, in what is now a regular occurrence, two immuno-oncology approvals. Even the new fili
Alcobra CEO Yaron Daniely admits that drug development for attention deficit hyperactivity disorder (ADHD) is a "road well-traveled," but says his Tel Aviv, Israel-based company is forging a new path
High levels of unmet medical need and the staggering direct and indirect costs of mental health disorders – $2.5 trillion worldwide in 2010, according to the National Institutes of Health ’s Nati
Finally armed with the tools to investigate the onset of fragile X syndrome, the most common genetic form of intellectual disability, researchers have elucidated the intracacies of its mechanism and a